EBS

#3046
Emergent Biosolutions, Inc.
8.0600 USD
+0.37%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
8.0301
8.0750
Intervallo Annuale
7.7400
11.4600
Variazione giornaliera
+0.37%
Variazione Mensile
+0.25%
Variazione di 6 mesi
-24.81%
Variazione Annuale
-24.81%
Chiusura Precedente
8.0300
Apertura
8.0575
Minimo
8.0301
High
8.0750
Volume
159
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 417.2731 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr.Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry Case Farmaceutiche - Specialistico e Generico
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
13.29
Rapporto prezzo/fatturato
0.94

Emergent BioSolutions Inc

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

Notizie